Shares of Johnson & Johnson JNJ,
gained 1.7% in pre-sale trading on Thursday, the day after a study published in the New England Journal of Medicine showed that the COVID-19 vaccine candidate produced neutral antibody titers in 100% of around 800 adult participant under 55 years of age 57. (Some of the data from the Phase 1/2 clinical trial were published in preliminary form in September.) them, which reflects the persistence of the immune response obtained from Ad26.COV2.S, ”the researchers wrote in the NEJM. The company’s COVID-19 experimental vaccine candidate is a single-dose vaccine, although the Phase 1/2 test also involves a group of participants who receive two doses. It is also currently being tested in a Phase 3 clinical trial. J&J said they plan to share additional data from this trial on the immune response in adults over 55 later this month, and They also plan to release high-end data from the Phase 3 test sometime in January. Two vaccines have been approved by the U.S. Food and Drug Administration, both of which are two – dose mRNA vaccines. J&J is developing an adenovirus-based vaccine. J&J stock is up 7.7% over the past year, and the S&P 500 SPX,
has received 15.8%.